Autres langues VACY AS Oslo Bors

Actions

VACC

NO0010714785

Cours en clôture Oslo Bors Autres places de cotation			Varia. 5j.	Varia. 1 janv.
- ^PTS	-.--%		-.--%	-.--%

20/06	Nykode Therapeutics annonce des mises à jour sur sa plateforme de vaccins inversés lors de la réunion FOCIS 2024	CI
11/06	Nykode Therapeutics ASA annonce que le vaccin anti-cancer ARNm-LNP démontre une efficacité supérieure	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Nykode Therapeutics : Grant of share options	01/07
Nykode Therapeutics : Announces Updates on its Inverse Vaccine Platform at FOCIS 2024 Meeting	20/06
Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform at FOCIS 2024 Meeting	20/06
Nykode Therapeutics : presentation from ABGSC Seminar on Autoimmunity, Transplantation & Inflammation	11/06
Nykode Therapeutics ASA Announces mRNA-LNP Cancer Vaccine Demonstrates Superior Efficacy	11/06
Nykode Therapeutics : Q1 2024 Financial Results – presentation	14/05
Nykode Therapeutics AS Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05
Nykode Therapeutics : Q1 2024 Financial Results	14/05
Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination with KEYTRUDA® (Pembrolizumab) in Patients with HPV16-Positive High-Risk Locally Advanced Cervical Cancer	14/05
Nykode Therapeutics : reports Q1 2024 Financial Results	14/05
Nykode Therapeutics Launches Phase 2 Clinical Trial for Cervical Cancer Vaccine	19/04
Nykode Therapeutics : Remuneration Report 2023	19/04
Nykode Therapeutics ASA Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer	19/04
Nykode Therapeutics Announces Topline Conclusions Affirming Prolonged Clinical Benefits from Matured Survival Data in Phase 2 C-02 Trial in Advanced Cervical Cancer	21/03
Nykode Therapeutics ASA Announces Advances in the Inverse Vaccine Platform with the Potential to Treat Autoimmune Diseases	19/03
Nykode Therapeutics AS Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/02
Nykode Therapeutics AS Reports Earnings Results for the Full Year Ended December 31, 2023	28/02
Nykode Therapeutics Announces Expansion of Oncology Pipeline Aiming to Reduce the Burden of Colorectal Cancer	14/12
Nykode Therapeutics AS Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	15/11
Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider	27/10/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues VACY AS Oslo Bors

Actions

VACC

NO0010714785

Autres langues

Filtres